Percorrer por tipo de recurso "Editorial"
A mostrar 1 - 8 de 8
Resultados por página
Opções de ordenação
- Editorial: Advanced techniques against food fraudPublication . Lei, Hongtao; Castanheira, Isabel; Guan, TianNo abstract available
- Editorial: Empowering Early Career Researchers In Psychiatry: Advancing Autism ResearchPublication . Caruso, Angela; Rasga, Célia; Fulceri, Francesca; Scattoni, Maria Luisa; Micai, MartinaNo abstract available
- Editorial: World antimicrobial awareness weekPublication . Hammoudi Halat, Dalal; Kassem, Issmat I; Osman, Marwan; Manageiro, VeraNo abstract available
- The Empty Medicine Cabinet: Urgent Action Needed to Resolve TB Drug Shortages in EuropePublication . Goletti, D.; Cirillo, D.M.; Lange, C.; Tiberi, S.; Günther, G.; Petrone, L.; Kuksa, L.; Opota, O.; Akkerman, O.; Podlekareva, D.; Guglielmetti, L.; Duarte, R.No abstract available.
- ERS Congress 2024: highlights from the Respiratory Infections AssemblyPublication . Jonckheere, Leander; Papadopoulou, Efthymia; Piedepalumbo, Federica; Akkerman, Onno W.; Duarte, Raquel; Premuda, ChiaraExtract: The 2024 European Respiratory Society (ERS) Congress in Vienna, Austria, brought together leading experts worldwide to address some of the most pressing challenges in respiratory medicine. In the field of respiratory infections, the congress highlighted notable advancements, particularly regarding pulmonary aspergillosis, tuberculosis (TB) and cystic fibrosis (CF), reflecting the rapidly evolving landscape in this area. This article aims to provide an overview of the key highlights from the congress in the field of respiratory infections, offering insights into the latest research, treatment innovations and ongoing challenges in managing these complex respiratory diseases.
- The Invisible Face of COVID-19Publication . Duarte, Raquel; Aguiar, AnaExtract: The COVID-19 pandemic has left indelible marks on the global landscape, disrupting lives, economies, and health systems. The immediate, visible consequences of the pandemic include overwhelmed healthcare systems, with hospitals stretched beyond capacity, leading to delayed care and strained resources¹,². Staggering mortality rates became a grim hallmark as COVID-19 claimed millions of lives worldwide. Economically, global lockdowns disrupted supply chains, shuttered businesses, and caused massive job losses, plunging countless families into financial insecurity³. The urgency of vaccine development and distribution brought hope and highlighted disparities in access, underscoring systemic inequities between high- and low-income countries. While these visible effects dominated public discourse, they represent only part of the pandemic’s multifaceted impact. A significant portion of its impact remains hidden beneath the surface. These invisible damages, often overshadowed by immediate crises, have profound implications for public health and societal resilience. Understanding these hidden consequences is essential to formulating effective recovery strategies and building resilience against future crises. Addressing both visible and invisible impacts is crucial for constructing a comprehensive narrative of the pandemic’s effects and implementing holistic solutions.
- Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacyPublication . Kuksa, L.; Andrejak, C.; Haecker, B.; Bothamley, G.; Calcagno, A.; Cirillo, D. M.; Duarte, Raquel; Fatima, R.; Ferlazzo, G.; Guglielmetti, L.; Günther, G.; Hewison, C.; Horsburgh, C.R.; Jäger, T.; Kalancha, Y.; Otto-Knapp, R.; Kranzer, K.; Lillebaek, T.; Marks, G.; Middelkoop, K.; Motta, I.; Rabinova, V.; Sommerfeld, P.; Tattevin, P.; Lange, C.Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, "when antibiotics used for the latter form of TB do not work or cause unacceptable side effects." This restricted use implies that the older, prolonged and poorly tolerated regimens remain the recommended treatment for most cases of drug-resistant TB. The authors, representing many respiratory groups and societies, call for the label expansion of pretomanid to align with global guidelines, allowing for broader use.
- WHO online guide on the use of digital technologies for tuberculosis programmesPublication . Akkerman, Onno W.; Falzon, Dennis; Migliori, Giovanni Battista; Konstantynovska, Olha; Eyuboglu, Fusun Oner; Sismanidis, Charalambos; Kanchar, Avinash; Duarte, RaquelExtract: In 2015, the World Health Organization (WHO)'s Global Tuberculosis Programme, the European Respiratory Society (ERS), and global experts released a collaborative agenda to enhance the use of digital technologies to end tuberculosis (TB) as a global public health threat, aligned to the United Nations Sustainable Development Goals and WHO's post-2015 End TB Strategy.